Risk factors for diabetes mellitus after acute pancreatitis: a systematic review and meta-analysis.

acute pancreatitis (AP) diabetes mellitus gastrointestinal disorders pancreatitis—complications prediabetes risk factor (RF)

Journal

Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047

Informations de publication

Date de publication:
2023
Historique:
received: 12 07 2023
accepted: 12 12 2023
medline: 24 1 2024
pubmed: 24 1 2024
entrez: 24 1 2024
Statut: epublish

Résumé

Within 5 years of having acute pancreatitis (AP), approximately 20% of patients develop diabetes mellitus (DM), which later increases to approximately 40%. Some studies suggest that the prevalence of prediabetes (PD) and/or DM can grow as high as 59% over time. However, information on risk factors is limited. We aimed to identify risk factors for developing PD or DM following AP. We systematically searched three databases up to 4 September 2023 extracting direct, within-study comparisons of risk factors on the rate of new-onset PD and DM in AP patients. When PD and DM event rates could not be separated, we reported results for this composite outcome as PD/DM. Meta-analysis was performed using the random-effects model to calculate pooled odds ratios (OR) with 95% confidence intervals (CI). Of the 61 studies identified, 50 were included in the meta-analysis, covering 76,797 participants. The studies reported on 79 risk factors, and meta-analysis was feasible for 34 risk factor and outcome pairs. The odds of developing PD/DM was significantly higher after severe and moderately severe AP (OR: 4.32; CI: 1.76-10.60) than mild AP. Hypertriglyceridemic AP etiology (OR: 3.27; CI: 0.17-63.91) and pancreatic necrosis (OR: 5.53; CI: 1.59-19.21) were associated with a higher risk of developing PD/DM. Alcoholic AP etiology (OR: 1.82; CI: 1.09-3.04), organ failure (OR: 3.19; CI: 0.55-18.64), recurrent AP (OR: 1.89; CI: 0.95-3.77), obesity (OR: 1.85; CI: 1.43-2.38), chronic kidney disease (OR: 2.10; CI: 1.85-2.38), liver cirrhosis (OR: 2.48; CI: 0.18-34.25), and dyslipidemia (OR: 1.82; CI: 0.68-4.84) were associated with a higher risk of developing DM. Severe and moderately severe AP, alcoholic and hypertriglyceridemic etiologies, pancreatic necrosis, organ failure, recurrent acute pancreatitis and comorbidities of obesity, chronic kidney disease liver disease, and dyslipidemia are associated with a higher risk of developing PD or DM. https://www.crd.york.ac.uk/prospero/, identifier CRD42021281983.

Identifiants

pubmed: 38264039
doi: 10.3389/fmed.2023.1257222
pmc: PMC10803425
doi:

Types de publication

Systematic Review

Langues

eng

Pagination

1257222

Informations de copyright

Copyright © 2024 Zahariev, Bunduc, Kovács, Demeter, Havelda, Budai, Veres, Hosszúfalusi, Erőss, Teutsch, Juhász and Hegyi.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Auteurs

Olga Julia Zahariev (OJ)

Centre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Institute of Pancreatic Diseases, Semmelweis University, Budapest, Hungary.
Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary.

Stefania Bunduc (S)

Centre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.

Adrienn Kovács (A)

Centre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Department of Internal Medicine and Hematology, Semmelweis University, Budapest, Hungary.

Dóra Demeter (D)

Centre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Dietetic Services, Central Hospital of Northern Pest - Military Hospital, Budapest, Hungary.

Luca Havelda (L)

Centre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Institute of Pancreatic Diseases, Semmelweis University, Budapest, Hungary.

Bettina Csilla Budai (BC)

Centre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Institute of Pancreatic Diseases, Semmelweis University, Budapest, Hungary.

Dániel Sándor Veres (DS)

Centre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Department of Biophysics and Radiation Biology, Semmelweis University, Budapest, Hungary.

Nóra Hosszúfalusi (N)

Centre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Department of Internal Medicine and Hematology, Semmelweis University, Budapest, Hungary.

Bálint Mihály Erőss (BM)

Centre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Institute of Pancreatic Diseases, Semmelweis University, Budapest, Hungary.
Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary.

Brigitta Teutsch (B)

Centre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary.

Márk Félix Juhász (MF)

Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary.
Heim Pál National Pediatric Institute, Budapest, Hungary.

Péter Hegyi (P)

Centre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Institute of Pancreatic Diseases, Semmelweis University, Budapest, Hungary.
Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary.
Translational Pancreatology Research Group, Interdisciplinary Center of Excellence for Research Development and Innovation University of Szeged, Szeged, Hungary.

Classifications MeSH